ROCHESTER, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)HUNTINGTON STUDY GROUP LTD, founded in 2012, is a community nonprofit in the Diseases & Disorders sector that reported $5.0M in total revenue in fiscal year 2024. Revenue fell 21% from the prior year — a significant decline worth monitoring.
THE HUNTINGTON STUDY GROUP (HSG) IS DEDICATED TO THE MISSION: TO SEEK TREATMENTS THAT MAKE A DIFFERENCE TO THOSE AFFECTED BY HUNTINGTON DISEASE. DESCRIPTION CONTINUED ON SCHEDULE O.SPECIFICALLY, THE HSG FOCUSES ON THE CONCEPTION, CONDUCT, ANALYSES, SCIENTIFIC REPORTING, AND COMMUNICATION OF CLINICAL RESEARCH, INCLUDING TREATMENT AND OBSERVATIONAL TRIALS, AIMED AT RELIEVING THE BURDENS AND SLOWING THE PROGRESSION OF HD. THE HSG 1) IDENTIFIES AND PRIORITIZES INITIATIVES THAT CAN HAVE AN IMPACT ON PATIENT CARE; 2) ADVANCES KNOWLEDGE ABOUT THE CAUSE, DISEASE PROGRESSION AND TREATMENT OF HD AND RELATED DISORDERS; AND 3) COLLABORATES WITH GOVERNMENT, FOUNDATIONS, INDUSTRY, AND THE HD COMMUNITY TO EFFECTIVELY PLAN, EXECUTE AND DISSEMINATE RESEARCH AND NEW KNOWLEDGE RELATED TO HD.
THE HSG IS A NETWORK OF CLINICIANS, RESEARCH INVESTIGATORS, SCIENTISTS AND HUNTINGTON DISEASE (HD) EXPERTS, LARGELY FROM ACADEMIC/RESEARCH INSTITUTIONS WORLDWIDE WORKING TOGETHER WITH A VARIETY OF...
THE HSG IS A NETWORK OF CLINICIANS, RESEARCH INVESTIGATORS, SCIENTISTS AND HUNTINGTON DISEASE (HD) EXPERTS, LARGELY FROM ACADEMIC/RESEARCH INSTITUTIONS WORLDWIDE WORKING TOGETHER WITH A VARIETY OF SPONSORS (GOVERNMENT, INDUSTRY, FOUNDATION) TO DEVELOP TREATMENTS THAT MAKE A DIFFERENCE FOR HD PATIENTS AND FAMILIES. WE PARTNER WITH HD CARE AND ADVOCACY GROUPS IN ORDER TO FULFILL OUR MISSION MOST EFFECTIVELY.DESCRIPTION CONTINUED ON SCHEDULE O.THE HSG HAS CARRIED OUT COOPERATIVE THERAPEUTIC RESEARCH SINCE 1993, BEGINNING WITH THE DEVELOPMENT OF THE UNIFIED HUNTINGTON'S DISEASE RATING SCALE (UHDRS) AND LONGITUDINAL DATABASE. THE HSG, THROUGH CLINICAL TRIALS, HAS BROUGHT THE ONLY TWO FDA-APPROVED HD TREATMENTS (TETRABENAZINE AND DUTETRABENAZINE) TO MARKET. WE CONTINUE TO SERVE OUR CONSTITUENTS THROUGH CLINICAL RESEARCH STUDIES. THE HSG HAS PARTNERED WITH PHARMACEUTICAL COMPANIES, PRIVATE FOUNDATIONS, THE NATIONAL INSTITUTES OF HEALTH (NIH), AND THE FDA ORPHAN DRUG PRODUCTS DIVISIONS IN DEVELOPING AND CONDUCTING TRIALS AND OBSERVATIONAL STUDIES.THE HSG IS COMMITTED TO 1) ADVANCE KNOWLEDGE ABOUT THE CAUSE, DISEASE PROGRESSION AND TREATMENT OF HD AND RELATED DISORDERS; 2) DEVELOPMENT, ACCESS TO, AND MAINTENANCE OF STUDY DATABASES; 3) FULL DISCLOSURE OF RESEARCH RESULTS IN SCIENTIFIC JOURNALS AFTER INDEPENDENT EXPERT REVIEW; 4) PROTECTION AGAINST CONFLICT OF INTEREST; 5) UNIFORM CONTRACTING AND SUB-CONTRACTING ACROSS ALL RESEARCH SITES; AND 6) DEMOCRATIC GOVERNANCE OF ITS ORGANIZATIONS AND ACTIVITIES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $5,041,772 | $6,359,880 | -0.2% |
| Expenses | $4,916,902 | $6,564,085 | -0.3% |
| Net Income | $124,870 | $-204,205 | -1.6% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| JONI STEINMAN | TREASURER (UNTIL NOV. 2024) | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| SHARI KINEL JD | CEO/SECRETARY (UNTIL 7/3/24) | 40.00 |
Officer
Director
|
$252,692 | $29,571 | $282,263 |
| PETER SCHMIDT PHD | CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| WILLIAM HOH | VICE CHAIR | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| ARVIND SREEDHARAN | BOARD MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| DANIEL CLAASSEN | CEO (BEGIN 9/1/24) | 40.00 |
Officer
Director
|
$155,934 | $5,700 | $161,634 |
| MICHAEL LENTINE | CFO | 40.00 |
Officer
|
$226,668 | $9,077 | $235,745 |
| ANNE VAN DUSEN | COO | 40.00 |
Highest
|
$259,537 | $20,080 | $279,617 |
| ELIZABETH DE BLIECK | SR. DIR, PROJECT MANAGEMENT | 40.00 |
Highest
|
$146,924 | $7,268 | $154,192 |
| ELISE KAYSON-RUBIN | VP OF CLINICAL OPERATIONS | 40.00 |
Highest
|
$125,483 | $11,231 | $136,714 |
| MELISSA AUSTIN | DIR, CLINICAL OPERATIONS | 40.00 |
Highest
|
$132,625 | $27,848 | $160,473 |
| KELLEY MORGAN | SR. PROJECT MANAGER | 40.00 |
Highest
|
$121,595 | $18,739 | $140,334 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $5,041,772 | $4,916,902 | $8,061,578 | $124,870 |
| 2023 | $6,359,880 | $6,564,085 | $8,173,182 | $-204,205 |
| 2022 | $6,746,002 | $6,756,731 | $8,704,616 | $-10,729 |
| 2021 | $9,967,496 | $9,091,521 | $10,251,900 | $875,975 |
| 2020 | $11,167,411 | $10,180,312 | $7,657,910 | $987,099 |
| 2019 | $13,110,561 | $12,788,592 | $7,722,690 | $321,969 |
| 2018 | $9,752,778 | $9,546,664 | $5,832,539 | $206,114 |
Compare HUNTINGTON STUDY GROUP LTD with other nonprofits in New York and across the country.